Multiple Sclerosis
FDA/CDC
Stroke, arterial dissection events reported with Lemtrada, FDA says
Rare but serious events described in multiple sclerosis patients given alemtuzumab (Lemtrada) prompts new warning.
Conference Coverage
Fatigue in MS: Common, often profound, tough to treat
BERLIN – Cognitive behavioral therapy carries the best evidence to treat MS-related fatigue.
Conference Coverage
Particular lesions early after CIS predict long-term MS disability
Conference Coverage
FDA urged to bring rheumatologists into gadolinium safety discussion
Latest News
FDA warns stopping fingolimod linked to severe MS worsening
The FDA has identified 35 cases of severely increased disability accompanied by new MRI lesions that occurred 2-24 weeks after patients stopped...
Medical Education Library
(Video) Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis Video Discussion
Conference Coverage
MS disease activity returns in one-third after fingolimod withdrawal
BERLIN – Risk factors for higher disease activity include younger age at diagnosis, shorter disease duration, and stopping more than 2 months...
Conference Coverage
Anti-MOG antibodies associated with non-MS, monophasic demyelinating disease in young children
BERLIN – Age and anti-MOG antibody status may help to predict a non-MS diagnosis.
Conference Coverage
Demyelinating diseases, especially MS, disrupt normal brain development in children
Conference Coverage
Alemtuzumab switch linked to good MS outcomes